Ajinomoto Company, Inc.
FDA inspection history across 2 sites, 2025
- 2
- Form 483s
Every document, by year
- Form 483
2025: two Form 483s.
The story so far
Built from the dates and citations on the documents themselves.
- 2025Two Form 483s, at Kawasaki, Japan and Kawasaki -City. Kanagawa, Japan.
- 2025The longest 483 on file: 3 observations over 11 pages at Kawasaki, Japan.
Cited most
Across all Ajinomoto Company observations on file
- 21 CFR 211.110Sampling and testing of in-process materials and drug products1
- 21 CFR 211.160General requirements1
- 21 CFR 211.192Production record review1
- 21 CFR 211.194Laboratory records1
- 21 CFR 211.65Equipment construction1
The complete Ajinomoto Company file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Kawasaki, Japan
One Form 483 · 2025 · 3 observations
Latest: Form 483, Feb 21, 2025 →Kawasaki -City. Kanagawa, Japan
One Form 483 · 2025 · 3 observations
Latest: Form 483, Feb 21, 2025 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2025-02-21 | 483 Form 483 | Kawasaki, Japan | 3 | $99 |
| 2025-02-21 | 483 Form 483 | Kawasaki -City. Kanagawa, Japan | 3 | $99 |
Investigators on these documents
Matthew B. Casale (2)Apseege Jose E. Melendez (1)Vincent Thomas (1)
FEI number 3002806336 · most recent document Feb 21, 2025
About Ajinomoto Company, Inc.
How many FDA Form 483s has Ajinomoto Company, Inc. received?
FDA Intel has 2 Form 483s on file for Ajinomoto Company, Inc.; the most recent is dated Feb 21, 2025.
When was Ajinomoto Company, Inc. last inspected by FDA?
The most recent FDA inspection document on file for Ajinomoto Company, Inc. is a Form 483 dated Feb 21, 2025, for the site in Kawasaki, Japan.
What did FDA cite at Ajinomoto Company, Inc.?
The regulations cited most in the observations on file for Ajinomoto Company, Inc. are 21 CFR 211.110 (Sampling and testing of in-process materials and drug products), 1 time; 21 CFR 211.160 (General requirements), 1 time; 21 CFR 211.192 (Production record review), 1 time.